Romero-Ibarguengoitia Maria Elena, Rivera-Salinas Diego, Sarti Riccardo, Levi Riccardo, Mollura Maximiliano, Garza-Silva Arnulfo, Rivera-Cavazos Andrea, Hernández-Ruíz Yodira Guadalupe, Barco-Flores Irene Antonieta, González-Cantú Arnulfo, Sanz-Sánchez Miguel Ángel, Guimarães Júnior Milton Henriques, Pozzi Chiara, Barbieri Riccardo, Morales-Rodriguez Devany Paola, Texeira Mauro Martins, Rescigno Maria
Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
Vaccines (Basel). 2023 Apr 14;11(4):842. doi: 10.3390/vaccines11040842.
Comparisons among the different vaccines against SARS-CoV-2 are important to understand which type of vaccine provides more protection. This study aimed to evaluate the real-life efficacy through symptomatic infection and the humoral response of six different vaccines against SARS-CoV-2-BNT162b2, mRNA-1273, ChAdOx1-S, CoronaVac, Ad26.COV2, and Ad5-nCoV. This multicentric observational longitudinal study involved hospitals from Mexico and Brazil in which volunteers who received complete vaccination schemes were followed for 210 days after the last dose. SARS-CoV-2 Spike 1-2 IgG levels were taken before receiving the first vaccine, 21 days after each dose, and the last sample at six months (+/-1 month) after the last dose. A total of 1132 individuals exposed to five COVID-19 waves were included. All vaccines induced humoral responses, and mRNA vaccines had the highest antibody levels during follow-up. At six months, there was a decline in the SARS-CoV-2 Spike 1-2 IgG antibody titers of 69.5% and 36.4% in subjects with negative and positive history of infection respectively. Infection before vaccination and after complete vaccination scheme correlated with higher antibody titers. The predictors of infection were vaccination with CoronaVac compared to BNT162b2 and ChAdOx1-S. In the presence of comorbidities such as diabetes, rheumatoid arthritis, or dyslipidemia, CoronaVac lowered the risk of infection.
比较不同的抗SARS-CoV-2疫苗对于了解哪种类型的疫苗能提供更多保护很重要。本研究旨在通过症状性感染和六种不同的抗SARS-CoV-2疫苗（BNT162b2、mRNA-1273、ChAdOx1-S、科兴新冠疫苗、Ad26.COV2和Ad5-nCoV）的体液反应来评估实际疗效。这项多中心观察性纵向研究涉及墨西哥和巴西的医院，其中接受完整疫苗接种方案的志愿者在最后一剂疫苗接种后被随访210天。在接种第一剂疫苗前、每剂疫苗接种后21天以及最后一剂疫苗接种后六个月（±1个月）采集SARS-CoV-2刺突1-2 IgG水平。总共纳入了1132名经历了五波新冠疫情的个体。所有疫苗均诱导了体液反应，且在随访期间mRNA疫苗的抗体水平最高。六个月时，既往感染史为阴性和阳性的受试者中，SARS-CoV-2刺突1-2 IgG抗体滴度分别下降了69.5%和36.4%。接种疫苗前和完成疫苗接种方案后的感染与较高的抗体滴度相关。与BNT162b2和ChAdOx1-S相比，接种科兴新冠疫苗是感染的预测因素。在存在糖尿病、类风湿性关节炎或血脂异常等合并症的情况下，科兴新冠疫苗降低了感染风险。
